Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.58 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.33 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
| ▸ | WNT3A | P56704 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394000 | 1.00 | AHR (0.58) | AHRALPLFLT1GPR3STIM1 | |
| SCHEMBL8759431 | 0.84 | ALPL (0.48) | AHRALPLFLT1GPR3STIM1 | |
| SCHEMBL1752066 | 0.84 | AHR (0.48) | AHRGPR3CTNNB1WNT3A | |
| SCHEMBL3342338 | 0.78 | MEN1 (0.38) | AHRGPR3CTNNB1WNT3A | |
| SCHEMBL30177616 | 0.78 | MEN1 (0.38) | AHRGPR3CTNNB1WNT3A | |
| SCHEMBL1702010 | 0.77 | AHR (0.47) | AHRALPL | |
| SCHEMBL17244773 | 0.76 | STIM1 (0.39) | AHRALPLFLT1GPR3STIM1 | |
| SCHEMBL755256 | 0.76 | GAA (0.48) | AHRALPLFLT1GPR3STIM1 | |
| SCHEMBL17543892 | 0.76 | AHR (0.35) | AHRGPR3STIM1ORAI1AKR1B1 | |
| SCHEMBL30714928 | 0.75 | ALPL (0.34) | AHRALPLFLT1GPR3STIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522589-B2 | Synthesis of CRAC channel inhibitors | CALCIMEDICA, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-11905248-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240010638-A1 | IMPROVED SYNTHESIS OF CRAC CHANNEL INHIBITORS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2024-01-11 | — | — | US | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| EP-2970185-B1 | 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC)PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES | CORTEVA AGRISCIENCE LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230017045-A1 | PYRIDINE AND PYRIMIDINE CARBOXYLATE HERBICIDES AND METHODS OF USE THEREOF | DOW AGROSCIENCES LLC (US) | 2023-01-19 | — | — | US | disclosed |
| WO-2022101654-A1 | IMPROVED SYNTHESIS OF CRAC CHANNEL INHIBITORS | CALCIMEDICA, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| EP-2563759-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3965760-A1 | SYNTHESIS OF CRAC CHANNEL INHIBITORS | Calcimedica, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20220056053-A1 | SYNTHESIS OF CRAC CHANNEL INHIBITORS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2022-02-24 | — | — | US | disclosed |
| EP-2563776-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011139489-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139489-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-1595877-B1 | Process for the preparation of 5-bromo-2,2-difluorobenzo-(1,3)-dioxoles | SALTIGO GMBH (DE) | 2009-03-11 | — | — | EP | disclosed |
| US-7148365-B2 | Process for preparing 5-bromo-2,2-difluorobenzo-1,3-dioxoles | LANXESS DEUTSCHLAND GMBH (DE) | 2006-12-12 | — | — | US | disclosed |
| US-20050272942-A1 | Process for preparing 5-bromo-2,2-difluorobenzo-1,3-dioxoles | LANXESS DEUTSCHLAND GMBH (DE) | 2005-12-08 | — | — | US | disclosed |
| EP-1595877-A1 | Process for the preparation of 5-bromo-2,2-difluorobenzo-(1,3)-dioxoles | Lanxess Deutschland GmbH (DE) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272942-A1 | Process for preparing 5-bromo-2,2-difluorobenzo-1,3-dioxoles | BROX, DCPS, CYP4X1 | AHR 1400/4885ALPL 1017/4885FLT1 2755/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | AHR 371/4885ALPL 4772/4885FLT1 1677/4885 |
| US-20240010638-A1 | IMPROVED SYNTHESIS OF CRAC CHANNEL INHIBITORS | CACNA1E, CACNA1C, ORAI1 | AHR 2901/4885ALPL 4805/4885FLT1 4562/4885 |
| US-20230017045-A1 | PYRIDINE AND PYRIMIDINE CARBOXYLATE HERBICIDES AND METHODS OF USE THEREOF | PDXK, DPYD, DDT | AHR 166/4885ALPL 2550/4885FLT1 1216/4885 |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | AHR 3487/4885ALPL 4016/4885FLT1 4830/4885 |
| US-20220056053-A1 | SYNTHESIS OF CRAC CHANNEL INHIBITORS | CACNA1E, CACNA1C, ORAI1 | AHR 3545/4885ALPL 4789/4885FLT1 4526/4885 |
| US-11905248-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | AHR 3487/4885ALPL 4016/4885FLT1 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.